acute myeloid leukaemia (AML)
Biopharma’s acute myeloid leukaemia treatment gains orphan drug designation
Clinical-stage biopharmaceutical company, ASLAN Pharmaceuticals, has been granted orphan drug designation (ODD) for its treatment for acute myeloid leukaemia (AML) — ASLAN003 — by the US Food and Drug Administration (FDA). Read more
The top five tweets: From Keytruda to cyber-security — what did EPM readers click on this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more
Treatment for acute myeloid leukaemia receives FDA approval
Pfizer’s treatment for adults with newly diagnosed acute myeloid leukaemia whose tumors express the CD33 antigen (CD33-positive AML), Mylotarg (gemtuzumab ozogamicin), has been approved by the US Food and Drug Administration (FDA). Read more
Orphan drug designation received for acute myeloid leukaemia treatment
The US Food and Drug Administration (FDA) has granted orphan drug designation to SY-1425, which is an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist for the treatment of acute myeloid leukaemia (AML) from Syros Read more
